Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMABusiness Wire • 04/20/22
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial ResultsBusiness Wire • 03/01/22
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022Business Wire • 02/24/22
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMABusiness Wire • 01/19/22
OMER EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMERPRNewsWire • 12/20/21
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?Zacks Investment Research • 12/15/21
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 12/04/21
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 BillionBusiness Wire • 12/02/21
Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy TrialBusiness Wire • 11/05/21
Omeros' Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA VasculitisBusiness Wire • 11/05/21
Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High?Zacks Investment Research • 11/04/21